Susquehanna Fundamental Investments LLC Invests $3.33 Million in Haemonetics Co. (NYSE:HAE)

Susquehanna Fundamental Investments LLC bought a new position in shares of Haemonetics Co. (NYSE:HAE - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 42,599 shares of the medical instruments supplier's stock, valued at approximately $3,326,000. Susquehanna Fundamental Investments LLC owned about 0.08% of Haemonetics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Arizona State Retirement System increased its holdings in Haemonetics by 1.2% during the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock worth $1,160,000 after purchasing an additional 181 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after acquiring an additional 240 shares in the last quarter. HighTower Advisors LLC raised its holdings in Haemonetics by 7.8% in the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock valued at $262,000 after acquiring an additional 244 shares in the last quarter. TD Waterhouse Canada Inc. bought a new position in Haemonetics during the 4th quarter valued at $25,000. Finally, Xponance Inc. increased its position in shares of Haemonetics by 5.9% in the 4th quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier's stock worth $566,000 after purchasing an additional 404 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on HAE shares. JMP Securities decreased their price target on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and reduced their price objective for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Barrington Research lowered their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Finally, Raymond James reaffirmed a "strong-buy" rating and set a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $101.22.

Haemonetics Stock Performance

HAE stock traded down $0.46 on Monday, reaching $63.40. The company's stock had a trading volume of 62,582 shares, compared to its average volume of 863,320. The firm has a fifty day moving average of $62.73 and a two-hundred day moving average of $71.69. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The company has a market capitalization of $3.18 billion, a P/E ratio of 24.96, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. Haemonetics Co. has a 52 week low of $55.30 and a 52 week high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, analysts predict that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.